BCTX BriaCell Therapeutics Corp.
Financings ·
BriaCell sold 1,449,300 common shares at $3.25 in a best efforts offering for gross proceeds of $4.71 million. ThinkEquity LLC was sole placement agent, with a 7.5% cash fee and warrants for 72,465 shares, and the company's 10-K carries a going-concern warning.
BriaCell Therapeutics sold 5.4 million units at $5.59, each with a five-year warrant struck at $6.93. The best-efforts deal closed Jan. 15.
BriaCell's board approved a one-for-ten share consolidation to keep its Nasdaq listing, expected to take effect August 25, 2025, subject to approval from Nasdaq and the Toronto Stock Exchange.
Nasdaq closed BriaCell's bid price matter on February 12, 2025, after an August 2024 letter cited 30 consecutive business days with closing bids below $1.00.
BriaCell sold 762,500 common shares at $4.00 each through placement agent ThinkEquity. The $3.05 million in gross proceeds is before fees and expenses, and the agent also received warrants on 38,125 shares.
Our latest story on this, dated Jun 3, 2026: "BriaCell closes best efforts offering of 1,449,300 shares at $3.25, raising $4.71 million gross". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 3, 2026: "BriaCell closes best efforts offering of 1,449,300 shares at $3.25, raising $4.71 million gross". The story links the filing or release it is based on. Read the story.
BriaCell Therapeutics Corp. trades under the ticker BCTX on NASDAQ.
BriaCell Therapeutics Corp. is listed on NASDAQ.
Our directory records BriaCell Therapeutics Corp. under Not recorded.
aibio.space lists BriaCell Therapeutics Corp. among 2,820 public biotech companies and publishes its news here as stories appear.
Our latest story on BriaCell Therapeutics, dated Jun 3, 2026: "BriaCell closes best efforts offering of 1,449,300 shares at $3.25, raising $4.71 million gross". BriaCell sold 1,449,300 common shares at $3.25 in a best efforts offering for gross proceeds of $4.71 million. ThinkEquity LLC was sole placement agent, with a 7.5% cash fee and warrants for 72,465 shares, and the company's 10-K carries a going-concern warning. Source.
From our story of Jun 3, 2026: ThinkEquity LLC was sole placement agent, with a 7.5% cash fee and warrants for 72,465 shares, and the company's 10-K carries a going-concern warning. Source.
Our latest listing story, dated Aug 26, 2025: "BriaCell plans 1-for-10 share consolidation to meet Nasdaq listing rules". BriaCell's board approved a one-for-ten share consolidation to keep its Nasdaq listing, expected to take effect August 25, 2025, subject to approval from Nasdaq and the Toronto Stock Exchange. Source.
Press Follow on this page to add BriaCell Therapeutics to your Following list, or subscribe to the aibio.space newsletter. We have published 5 stories naming BriaCell Therapeutics so far, in Financings, Listings.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio